<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gabapentinoid poisoning and withdrawal</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gabapentinoid poisoning and withdrawal</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gabapentinoid poisoning and withdrawal</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kavita M Babu, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erica L Liebelt, MD, FACMT</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1766269022"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> are commonly prescribed medications for the treatment of seizure disorders, neuropathic pain (eg, postherpetic neuralgia), fibromyalgia, anxiety, post-traumatic stress disorder, and restless leg syndrome. Gabapentinoids are commonly ingested in self-harm attempts and often misused for their sedative and euphoric properties. These medications can cause lethargy or agitation in overdose, increase risk of death combined with opioids, and manifest a withdrawal syndrome.</p><p>This topic will discuss the evaluation and management of gabapentinoid poisoning and withdrawal. A summary table to facilitate emergency management is provided  (<a class="graphic graphic_table graphicRef141754" href="/z/d/graphic/141754.html" rel="external">table 1</a>). Their therapeutic use and a general discussion of evaluation and management of the poisoned patient are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/133187.html" rel="external">"Nonopioid pharmacotherapy for acute pain in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">"Approach to the child with occult toxic exposure"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a>.)</p><p></p><p class="headingAnchor" id="H3191408550"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Nearly 75,000 <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> exposures were reported to United States (US) poison control centers from 2013 to 2017 [<a href="#rid1">1</a>]. Seventy percent of these exposures were intentional ingestions, and more than 80 percent of the intentional exposures occurred during attempted suicide. The majority of gabapentin exposures involved other substances, such as sedative-hypnotics, antidepressants, antihypertensives, and opioids. During this five-year period, gabapentin exposures increased by 72 percent. </p><p>Misuse and diversion of <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> are increasingly recognized [<a href="#rid2">2,3</a>]. Gabapentinoids are often used as part of a multi-modal regimen for chronic pain or misused by individuals with an opioid use disorder (OUD). Among almost 13,000 individuals seeking OUD treatment from 2019 to 2020, 9 percent reported past-month non-medical gabapentin use [<a href="#rid4">4</a>]. In addition to oral intake of pills, increasingly reported routes of misuse include nasal insufflation (crushing the pills and "snorting"), rectal ("plugging"), smoking, and intravenous [<a href="#rid5">5,6</a>]. When used in combination with opioids, gabapentin and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> has been associated with a 50 to 70 percent increased risk of opioid-associated death [<a href="#rid7">7,8</a>]. Based on US post-mortem data from 2019 to 2020, an opioid was found in almost 90 percent of drug overdose deaths in which gabapentin was detected [<a href="#rid9">9</a>]. </p><p class="headingAnchor" id="H1746758648"><span class="h1">PHARMACOLOGY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> are classified as gabapentinoids because of their structural similarity to gamma aminobutyric acid (GABA). However, their mechanism of action occurs apart from GABA-A receptors. They bind to the alpha-2-delta subunit of a voltage-dependent calcium channel, inhibiting presynaptic calcium influx and release of excitatory neurotransmitters [<a href="#rid10">10</a>]. Gabapentin and pregabalin most likely do not bind the GABA-B receptor [<a href="#rid11">11</a>]. Pregabalin also modulates the release of several neurotransmitters including glutamate, noradrenaline, and substance P [<a href="#rid12">12</a>].</p><p>Long term gabapentinoid therapy can lead to the development of tolerance, dependence, and withdrawal symptoms with cessation of therapy [<a href="#rid13">13-16</a>]. (See <a class="local">'Withdrawal syndromes'</a> below.)</p><p class="headingAnchor" id="H2692944025"><span class="h1">PHARMACOKINETICS</span><span class="headingEndMark"> — </span>The pharmacokinetics of <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> are similar.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absorption </strong>– Both are rapidly absorbed with oral administration, have high (60-90 percent) oral bioavailability, and reach peak concentrations within one to four hours [<a href="#rid17">17,18</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distribution </strong>– Both have low plasma protein binding and a low (&lt;1 L/kg) volume of distribution [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism </strong>– Neither undergo metabolism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elimination </strong>– Both are eliminated unchanged by the kidneys. The elimination half-life is 4-6 hours but can be significantly prolonged in the setting of overdose or kidney failure [<a href="#rid20">20,21</a>]. Toxic effects are not expected to last beyond 24 hours in a patient with normal kidney function. </p><p></p><p class="bulletIndent1">Patients with chronic kidney disease require renal dosing adjustments since toxicity can develop from therapeutic dosing, given primarily renal elimination [<a href="#rid22">22,23</a>]. </p><p></p><p class="headingAnchor" id="H3488727712"><span class="h1">CLINICAL FEATURES OF OVERDOSE</span></p><p class="headingAnchor" id="H1871721508"><span class="h2">Normal vital signs</span><span class="headingEndMark"> — </span>Patients with isolated gabapentinoid overdoses usually do not have any significant changes in vital signs. Hypothermia or hyperthermia may reflect downtimes in ambient environments; fever from aspiration pneumonitis can occur in patients who aspirate. Mild tachycardia has been reported, and bradycardia can occur rarely [<a href="#rid24">24</a>]. Blood pressure and respiratory rate are typically within a normal range. </p><p class="headingAnchor" id="H4199947642"><span class="h2">CNS depression</span><span class="headingEndMark"> — </span>Isolated gabapentinoid overdoses typically cause only mild somnolence. Most patients will remain rousable to voice or tactile stimulation. The most common symptoms reported after <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> ingestion include sedation, dizziness, and ataxia [<a href="#rid24">24</a>]. In massive overdose, acute or chronic kidney impairment, or co-ingestion of other sedative (eg, alcohol, benzodiazepines, or opioids), patients may show signs of more pronounced central nervous system (CNS) depression (eg, lethargy, coma). However, massive gabapentin ingestions (up to 50 grams) have been reported with minimal sequelae [<a href="#rid25">25,26</a>]. </p><p>Patients may have mild miosis after gabapentinoid ingestion, similar to other sedative-hypnotic poisoning. </p><p class="headingAnchor" id="H118424910"><span class="h2">Myoclonus, seizures</span><span class="headingEndMark"> — </span>Multifocal and isolated myoclonus have been reported with <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> use and overdose and are more likely to occur in patients with impaired kidney function [<a href="#rid27">27-31</a>]. Increased neuromuscular tone (eg, clonus, rigidity, hyperreflexia) would not be expected in a gabapentin or pregabalin overdose. </p><p>Isolated seizures can occur following overdose of <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> [<a href="#rid24">24,31-34</a>]. Most reports describe a seizure lasting several minutes and resolving without intervention. Recurrent seizures can occur in rare cases.</p><p class="headingAnchor" id="H365099448"><span class="h2">Agitation, psychosis</span><span class="headingEndMark"> — </span>Psychotic symptoms such as visual and auditory hallucinations, agitation, and paranoia have been reported with <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> use [<a href="#rid35">35,36</a>]. One of these cases was associated with epileptiform discharges on electroencephalography and improved following benzodiazepine administration [<a href="#rid35">35</a>]. </p><p class="headingAnchor" id="H1194110310"><span class="h2">Myopathy</span><span class="headingEndMark"> — </span>There are case reports of gabapentin-induced myopathy and rhabdomyolysis, occasionally requiring renal replacement therapy [<a href="#rid37">37-40</a>]. </p><p class="headingAnchor" id="H2883810633"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>As with other suspected overdoses, the clinical approach to a patient with suspected gabapentinoid overdose involves collecting available history, a targeted physical examination, and relevant laboratory and electrocardiogram (ECG) findings. </p><p class="headingAnchor" id="H3564038584"><span class="h2">History</span><span class="headingEndMark"> — </span>The following are key elements of a clinical history in a suspected gabapentinoid overdose:</p><p class="bulletIndent1"><span class="glyph">●</span>Reasons to suspect overdose (eg, suicide note, witnessed, reported to bystanders)</p><p class="bulletIndent1"><span class="glyph">●</span>Time of ingestion or last dose</p><p class="bulletIndent1"><span class="glyph">●</span>Intent behind use (self-harm versus misuse)</p><p class="bulletIndent1"><span class="glyph">●</span>Suspected co-ingestants</p><p class="bulletIndent1"><span class="glyph">●</span>Names of other accessible medications </p><p class="bulletIndent1"><span class="glyph">●</span>Last time known well</p><p class="bulletIndent1"><span class="glyph">●</span>Prior history of self-harm attempts</p><p class="bulletIndent1"><span class="glyph">●</span>History of opioid use disorder, chronic renal insufficiency, or seizures</p><p></p><p class="headingAnchor" id="H360791034"><span class="h2">Examination</span><span class="headingEndMark"> — </span>A targeted physical examination should be performed to assess mental status, airway protection, focal neurologic deficit, evidence of self-injury, and for presence of toxidromes  (<a class="graphic graphic_table graphicRef71268" href="/z/d/graphic/71268.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H987672727"><span class="h2">Laboratory studies and ECG</span><span class="headingEndMark"> — </span>Routine laboratory and diagnostic testing of the patient with somnolence, including when a gabapentinoid ingestion is suspected, is aimed at excluding other diagnoses and includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Fingerstick blood glucose to rule out hypoglycemia as the cause of altered mental status </p><p class="bulletIndent1"><span class="glyph">●</span>Serum chemistries, creatinine, and creatine kinase to assess kidney function and exclude rhabdomyolysis</p><p class="bulletIndent1"><span class="glyph">●</span>Serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, salicylate, and ethanol concentrations to rule out these common co-ingestions</p><p class="bulletIndent1"><span class="glyph">●</span>ECG to screen for poisoning by drugs that affect the QRS or QTc intervals</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy test in females of childbearing age</p><p></p><p>Additional tests are obtained based upon historical and clinical findings. </p><p>Gabapentinoid serum concentrations are not routinely useful in the evaluation and management of the somnolent patient, including when a gabapentinoid ingestion is suspected. These assays are not routinely available in the emergency setting, do not reliably correlate with clinical findings since tolerance can develop, and do not aid in acute management due to long turn-around times. Serum concentrations may be helpful confirmatory forensic tests (eg, pediatric patient with altered mental status in whom gabapentinoid poisoning is suspected). Serum concentration can also be helpful in excluding gabapentinoid poisoning as the etiology of unexplained prolonged coma if the serum concentration is &lt;1 mg/L [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H135080170"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Gabapentinoid poisoning is a clinical diagnosis. The diagnosis should be suspected in a somnolent patient whose mental status does not improve after receiving <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>. In the absence of clear corroborating history (eg, self-report or witnessed ingestion), gabapentinoid poisoning should be considered a diagnosis of exclusion. Non-toxicologic and other toxicologic etiologies must be ruled out, especially conditions in which diagnostic delay will hold up critical interventions and definitive care.</p><p class="headingAnchor" id="H3375185027"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Gabapentinoid poisoning produces a sedative-hypnotic toxidrome characterized by depressed mental status and unremarkable vital signs  (<a class="graphic graphic_table graphicRef71268" href="/z/d/graphic/71268.html" rel="external">table 2</a>). In any suspected ingestion when the patient cannot provide a history, an exploration of alternative sources of information is warranted, including but not exclusive to emergency medical services, family members, pill bottles when available, medical records, and pharmacy information. Other common ingestions that present similar to gabapentinoid poisoning include:</p><p class="bulletIndent1"><span class="glyph">●</span>Ethanol and <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> intoxication, which can be assessed by obtaining serum concentrations. (See  <a class="medical medical_review" href="/z/d/html/333.html" rel="external">"Ethanol intoxication in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6487.html" rel="external">"Ethanol intoxication in children: Clinical features, evaluation, and management"</a> and  <a class="medical medical_review" href="/z/d/html/13844.html" rel="external">"Barbiturate (phenobarbital) poisoning"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Benzodiazepine, <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">zolpidem</a>, <a class="drug drug_general" data-topicid="10126" href="/z/d/drug information/10126.html" rel="external">zopiclone</a>, <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">trazodone</a>, and phenibut are examples of commonly misused sedatives that can only be excluded by history. (See  <a class="medical medical_review" href="/z/d/html/314.html" rel="external">"Benzodiazepine poisoning"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gamma hydroxybutyrate (GHB) intoxication, which often manifests severe central nervous system depression followed by abrupt awakening. GHB intoxication is difficult to distinguish from other causes of obtundation without a clear history. (See  <a class="medical medical_review" href="/z/d/html/307.html" rel="external">"Gamma hydroxybutyrate (GHB) intoxication"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atypical antipsychotic agents (eg, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>), which are commonly misused and intentionally ingested, can cause sedation as well as tachycardia and anticholinergic delirium. (See  <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects"</a> and  <a class="medical medical_review" href="/z/d/html/305.html" rel="external">"Anticholinergic poisoning"</a>.) </p><p></p><p>Sedation and coma  (<a class="graphic graphic_table graphicRef65571" href="/z/d/graphic/65571.html" rel="external">table 3</a>) are found in a wide range of medical and toxicologic conditions. Unless the diagnosis of gabapentinoid poisoning is obvious, other life-threatening, non-toxicologic causes must be considered in the differential diagnosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoglycemia must be excluded in every patient with altered mental status, even if gabapentinoid poisoning is suspected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with profound respiratory depression or cardiopulmonary instability, which is rare with isolated gabapentinoid overdoses, the presence of co-ingestants or non-toxicologic etiologies should be investigated [<a href="#rid27">27</a>]. A patient with partial improvement in mental status following <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> administration may have a gabapentinoid and opioid co-ingestion. (See  <a class="medical medical_review" href="/z/d/html/300.html" rel="external">"Acute opioid intoxication in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6504.html" rel="external">"Opioid intoxication in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Altered mental status in association with fever or leukocytosis raises concern for meningitis or other infections and warrants a thorough evaluation, often including assessment of the cerebral spinal fluid. (See  <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/1284.html" rel="external">"Viral encephalitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6043.html" rel="external">"Acute viral encephalitis in children: Pathogenesis, epidemiology, and etiology"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any focal neurologic findings or seizures raise concern for a central nervous system process such as stroke, intracranial hemorrhage, or encephalitis. (See  <a class="medical medical_review" href="/z/d/html/1083.html" rel="external">"Overview of the evaluation of stroke"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A history of trauma or clinical findings of injuries should prompt obtaining a head computed tomography (CT) scan. (See  <a class="medical medical_review" href="/z/d/html/13854.html" rel="external">"Initial management of trauma in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2421129212"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H715396303"><span class="h2">All patients: supportive care</span><span class="headingEndMark"> — </span>The initial management begins with rapidly assessing and addressing the patient's airway, breathing, and circulation. In patients who present with anything more than trivial sedation, we suggest establishing intravenous (IV) access and continuous cardiac monitoring. </p><p>Tachycardia and/or hypotension, which are unusual from an isolated gabapentinoid ingestion, should initially be managed with boluses of isotonic IV fluids and prompt an exploration for co-ingestant or another process (eg, infection). Vomiting, which commonly occurs following many ingestions, can be treated with <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a>. (See  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults", section on 'Supportive care'</a> and  <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose", section on 'Systematic evaluation: The "ABCDE" approach'</a>.)</p><p class="headingAnchor" id="H1197284181"><span class="h2">Limited role for gastrointestinal decontamination</span><span class="headingEndMark"> — </span>We do not perform routine gastrointestinal decontamination with activated charcoal (AC) in patients with isolated gabapentinoid ingestion since intoxication will often improve with supportive care and excretion of the gabapentinoid. Administering AC provides no additional benefits but can increase the risk of aspiration and complicate airway management if the patient becomes more sedated. (See  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Activated charcoal'</a>.)</p><p class="headingAnchor" id="H1149558835"><span class="h2">Management based on toxicity</span></p><p class="headingAnchor" id="H1554664980"><span class="h3">CNS depression</span><span class="headingEndMark"> — </span>Most patients with central nervous system (CNS) depression from gabapentinoid poisoning recover uneventfully without specific intervention. End tidal carbon dioxide (EtCO<sub>2</sub>; ie, capnography) is useful to monitor for hypoventilation. Oxygen should be administered as needed. Placing a nasopharyngeal airway (ie, nasal trumpet) may be sufficient to overcome upper airway obstruction from CNS depression and preclude the need for tracheal intubation. (See  <a class="medical medical_review" href="/z/d/html/267.html" rel="external">"Basic airway management in adults", section on 'Nasopharyngeal airway'</a> and  <a class="medical medical_review" href="/z/d/html/6383.html" rel="external">"Basic airway management in children", section on 'Nasopharyngeal airway'</a>.)</p><p>We do not administer <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> to a patient with suspected gabapentinoid poisoning. Flumazenil is a non-specific competitive antagonist of the benzodiazepine receptor on the GABA channel. It would not be expected to improve gabapentinoid intoxication and may precipitate benzodiazepine withdrawal if the patient has a benzodiazepine co-ingestion. Its use in the somnolent patient with benzodiazepine poisoning is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/314.html" rel="external">"Benzodiazepine poisoning", section on 'Role of antidote (flumazenil)'</a>.)</p><p>Tracheal intubation may be required if the patient is unable to protect their airway. (See  <a class="medical medical_review" href="/z/d/html/268.html" rel="external">"The decision to intubate", section on 'Is patency or protection of the airway at risk?'</a>.) </p><p class="headingAnchor" id="H3899907891"><span class="h3">Decreased respiratory rate</span><span class="headingEndMark"> — </span>In a somnolent patient with suspected gabapentinoid poisoning who has a low respiratory rate, we administer a trial of parenteral or intranasal <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>, given the high rate of opioid co-ingestion. Naloxone would not be expected to reverse the effects of the gabapentinoid itself but may improve mental status or respiration if the patient is also suffering opioid intoxication. (See  <a class="medical medical_review" href="/z/d/html/300.html" rel="external">"Acute opioid intoxication in adults", section on 'Basic measures and antidotal therapy'</a> and  <a class="medical medical_review" href="/z/d/html/6504.html" rel="external">"Opioid intoxication in children and adolescents", section on 'Naloxone'</a>.)</p><p>Tracheal intubation may be required if the respiratory status does not improve following <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>. (See  <a class="medical medical_review" href="/z/d/html/268.html" rel="external">"The decision to intubate", section on 'Is oxygenation or ventilation failing?'</a>.) </p><p class="headingAnchor" id="H1517036901"><span class="h3">Seizure</span><span class="headingEndMark"> — </span>Since most gabapentinoid-induced seizures are self-limited and brief, we do not administer antiseizure medication since it could exacerbate gabapentinoid-induced CNS depression. In a patient with recurrent seizures or prolonged seizures (&gt;5 minutes), benzodiazepine administration (eg, adults: <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> 4 mg IV; children: 0.1 mg/kg IV, maximum dose 4 mg) is the first-line therapy. If additional medications are needed, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> or <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> are preferred to <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> as the second-line therapy since they have greater efficacy for toxin-induced seizures. (See  <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose", section on '"D": Disability and neurological stabilization'</a> and  <a class="medical medical_review" href="/z/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management", section on 'In-hospital treatment'</a> and  <a class="medical medical_review" href="/z/d/html/6192.html" rel="external">"Management of convulsive status epilepticus in children", section on 'In-hospital treatment'</a>.)</p><p class="headingAnchor" id="H2325926896"><span class="h3">Myoclonus</span><span class="headingEndMark"> — </span>We suggest symptomatic management of myoclonus since it improves with discontinuation of the gabapentinoid. Dialysis has been reported to improve myoclonus in patients with chronic kidney disease [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H3705269264"><span class="h2">Patient with kidney impairment</span><span class="headingEndMark"> — </span>In a patient with severe gabapentinoid poisoning (eg, coma) with severe kidney impairment, we suggest performing extracorporal removal in addition to supportive care. There is no clear definition of severe gabapentinoid poisoning, but the need for mechanical ventilation for depressed mental status or respiratory failure is accepted by most experts. We define kidney impairment as acute kidney injury stage 2 or 3 using the Kidney Disease: Improving Global Outcomes (KDIGO) or stages III-V chronic kidney disease  (<a class="graphic graphic_table graphicRef140950" href="/z/d/graphic/140950.html" rel="external">table 4</a>). The duration of gabapentinoid toxicity is significantly prolonged in patients with severe kidney impairment. Both <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> are effectively cleared by hemodialysis [<a href="#rid20">20,21,43</a>]. (See  <a class="medical medical_review" href="/z/d/html/325.html" rel="external">"Enhanced elimination of poisons", section on 'Extracorporeal removal'</a>.)</p><p>The preferred extracorporeal removal modality is intermittent hemodialysis, which should be continued until the patient's clinical status improves. Our recommendations are in agreement with those of the Extracorporeal Treatments in Poisoning (EXTRIP) workgroup [<a href="#rid27">27</a>]. </p><p>The evidence for hemodialysis in <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> poisoning is based on case reports and measured hemodialysis clearance, which is typically &gt;100 mL/min in pharmacokinetic studies [<a href="#rid20">20,21,27,43</a>]. In patients with kidney failure, hemodialysis has resulted in rapid improvement in mental status and extubation (if the patient required tracheal intubation) [<a href="#rid44">44-50</a>]. Since prolonged mechanical ventilation has potential complications (eg, ventilator-associated pneumonia), significantly shortening the duration outweighs potential complications of hemodialysis, especially in a patient with chronic kidney disease who has established dialysis access. </p><p>In a patient with normal kidney function, we think the potential complications of hemodialysis outweigh the benefit of shortening the course of toxicity since most patients will improve within 24 hours without specific interventions.</p><p class="headingAnchor" id="H495695204"><span class="h1">DISPOSITION</span><span class="headingEndMark"> — </span>Patients who have significant respiratory depression (eg, require mechanical ventilation), hypotension, or have been exposed to a hazardous co-ingestant should be admitted to a critical care setting.</p><p></p><p>Most patients with an isolated gabapentinoid ingestion can be safely discharged or cleared for psychiatric evaluation following an observation period of four to six hours, provided that any concerning symptoms, such as central nervous system depression, have resolved. The patient should be able to ambulate safely and without assistance prior to discharge. Patients with persistent signs of intoxication beyond six hours should be admitted to a monitored setting until symptoms resolve.</p><p>Since gabapentinoids are frequently ingested in self-harm attempts, a patient with a suspected self-harm attempt should be urgently referred for behavioral health evaluation.</p><p>If the patient has an opioid co-ingestion or opioid use disorder, they should be counseled about the risk of respiratory depression from gabapentinoid co-ingestion and offered referral to substance use disorder treatment. </p><p class="headingAnchor" id="H2038075424"><span class="h1">WITHDRAWAL SYNDROMES</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> withdrawal ranges in severity. Withdrawal can occur following abrupt cessation with misuse or prescribed dosing [<a href="#rid51">51</a>]. Withdrawal symptoms have been reported to start as early as 12 hours after cessation of use, but in most cases start after 24 to 48 hours [<a href="#rid14">14,52</a>].</p><p>Common symptoms are anxiety and insomnia, but can also include diaphoresis, gastrointestinal discomfort, diarrhea, tremors, tachycardia, hypertension, agitation, delirium, disorientation, paranoia, hallucinations, and rarely seizures [<a href="#rid14">14,51,53-56</a>].</p><p>Reinstitution of the prior dose of <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> alleviates withdrawal symptoms [<a href="#rid14">14,52</a>]. This can be followed by a taper if the goal is cessation. An evidence-based taper protocol does not exist. One week is felt to be the minimal duration, but it is important to monitor for recurrence of withdrawal symptoms and extend the taper if needed [<a href="#rid57">57</a>]. Based on anecdotal reports, a reasonable initial approach is decreasing the daily dose by 300 mg every four days to one week. Benzodiazepines are typically ineffective for gabapentin withdrawal. A case series reported three patients who were successfully managed with a <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> taper [<a href="#rid53">53</a>].</p><p>A neonatal <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> withdrawal syndrome has been reported [<a href="#rid58">58,59</a>]. (See  <a class="medical medical_review" href="/z/d/html/5010.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Clinical features and diagnosis", section on 'Clinical manifestations of NAS'</a>.)</p><p class="headingAnchor" id="H1119573751"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H1501390489"><span class="h2">Regional poison centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H2514251641"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114014.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"</a>.)</p><p class="headingAnchor" id="H3366698195"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacology</strong> – Gabapentinoids are commonly ingested in self-harm attempts and often misused for their sedative and euphoric properties. They are eliminated unchanged by the kidneys. (See <a class="local">'Pharmacology'</a> above and <a class="local">'Pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features of overdose</strong> – Patients with isolated gabapentinoid overdoses typically only develop mild somnolence without significant vital sign derangements. Less common symptoms include myoclonus, agitation, hallucinations, rhabdomyolysis, and isolated seizures, which can occur following overdose and typically resolve after several minutes without intervention. A summary table to facilitate emergency management is provided  (<a class="graphic graphic_table graphicRef141754" href="/z/d/graphic/141754.html" rel="external">table 1</a>). (See <a class="local">'Clinical features of overdose'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Routine laboratory and diagnostic testing is aimed at excluding other diagnoses and includes serum chemistries, creatinine, creatine kinase; serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, salicylate, and ethanol concentrations; and electrocardiogram (ECG). (See <a class="local">'Laboratory studies and ECG'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– Gabapentinoid poisoning should be suspected in a somnolent patient whose mental status does not improve after receiving <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>. In the absence of clear corroborating history, it is a diagnosis of exclusion. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– Most patients with central nervous system depression from gabapentinoid poisoning recover uneventfully with supportive care without specific intervention. Tracheal intubation may be required if the patient is unable to protect their airway. We do not administer <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> since it may precipitate benzodiazepine withdrawal if the patient has a benzodiazepine co-ingestion. We do not routinely administer activated charcoal in a patient with isolated gabapentinoid ingestion since intoxication will often improve with supportive care. (See <a class="local">'All patients: supportive care'</a> above and <a class="local">'Limited role for gastrointestinal decontamination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Decreased respiratory rate</strong> – In a somnolent patient with a low respiratory rate, we administer a trial of parenteral or intranasal <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>, which would not be expected to reverse the effects of the gabapentinoid itself. Naloxone may improve mental status or respiration if the patient is also suffering opioid intoxication, which are common co-ingestants. (See <a class="local">'Decreased respiratory rate'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Seizure </strong>– We do not administer antiseizure medication since most seizures are self-limited and brief. In a patient with recurrent or prolonged seizures, we administer benzodiazepines (eg, adults: <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> 4 mg IV; children: 0.1 mg/kg IV, maximum dose 4 mg). (See <a class="local">'Seizure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Kidney impairment</strong> – In a patient with severe gabapentinoid poisoning with severe kidney impairment  (<a class="graphic graphic_table graphicRef140950" href="/z/d/graphic/140950.html" rel="external">table 4</a>), we suggest hemodialysis in addition to supportive care (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The prolonged duration of gabapentinoid toxicity with severe kidney impairment can be shortened since both <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> are effectively cleared by hemodialysis. We define severe poisoning as the need for mechanical ventilation for depressed mental status or respiratory failure. (See <a class="local">'Patient with kidney impairment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Withdrawal syndromes</strong> – Abrupt cessation of gabapentinoid use can cause a withdrawal syndrome that may include anxiety, insomnia, diaphoresis, gastrointestinal discomfort, tremors, tachycardia, hypertension, delirium, agitation, paranoia, hallucinations, and rarely seizures. These are treated with reinstitution of the gabapentinoid followed by a gradual taper. (See <a class="local">'Withdrawal syndromes'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Reynolds K, Kaufman R, Korenoski A, et al. Trends in gabapentin and baclofen exposures reported to U.S. poison centers. Clin Toxicol (Phila) 2020; 58:763.</a></li><li><a class="nounderline abstract_t">Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction 2016; 111:1160.</a></li><li><a class="nounderline abstract_t">Evoy KE, Morrison MD, Saklad SR. Abuse and Misuse of Pregabalin and Gabapentin. Drugs 2017; 77:403.</a></li><li><a class="nounderline abstract_t">Ellis MS, Buttram ME, Kasper ZA. Nonmedical use of gabapentin and opioid agonist medications in treatment-seeking individuals with opioid use disorder. Drug Alcohol Depend 2022; 234:109400.</a></li><li><a class="nounderline abstract_t">Khalid Z, Hennen MA, Aldana-Bernier L. Gabapentin Abuse by Nasal Insufflation: A Case Report. J Clin Psychopharmacol 2019; 39:89.</a></li><li><a class="nounderline abstract_t">Elsayed M, Zeiss R, Gahr M, et al. Intranasal Pregabalin Administration: A Review of the Literature and the Worldwide Spontaneous Reporting System of Adverse Drug Reactions. Brain Sci 2019; 9.</a></li><li><a class="nounderline abstract_t">Gomes T, Juurlink DN, Antoniou T, et al. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLoS Med 2017; 14:e1002396.</a></li><li><a class="nounderline abstract_t">Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the Risk for Opioid-Related Death: A Nested Case-Control Study. Ann Intern Med 2018; 169:732.</a></li><li><a class="nounderline abstract_t">Mattson CL, Chowdhury F, Gilson TP. Notes from the Field: Trends in Gabapentin Detection and Involvement in Drug Overdose Deaths - 23 States and the District of Columbia, 2019-2020. MMWR Morb Mortal Wkly Rep 2022; 71:664.</a></li><li><a class="nounderline abstract_t">van Hooft JA, Dougherty JJ, Endeman D, et al. Gabapentin inhibits presynaptic Ca(2+) influx and synaptic transmission in rat hippocampus and neocortex. Eur J Pharmacol 2002; 449:221.</a></li><li><a class="nounderline abstract_t">Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006; 6:108.</a></li><li><a class="nounderline abstract_t">Lauria-Horner BA, Pohl RB. Pregabalin: a new anxiolytic. Expert Opin Investig Drugs 2003; 12:663.</a></li><li><a class="nounderline abstract_t">Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 2011; 52:826.</a></li><li><a class="nounderline abstract_t">Mersfelder TL, Nichols WH. Gabapentin: Abuse, Dependence, and Withdrawal. Ann Pharmacother 2016; 50:229.</a></li><li><a class="nounderline abstract_t">Hardman MI, Sprung J, Weingarten TN. Acute phenibut withdrawal: A comprehensive literature review and illustrative case report. Bosn J Basic Med Sci 2019; 19:125.</a></li><li><a class="nounderline abstract_t">Samokhvalov AV, Paton-Gay CL, Balchand K, Rehm J. Phenibut dependence. BMJ Case Rep 2013; 2013.</a></li><li><a class="nounderline abstract_t">Gidal BE, Radulovic LL, Kruger S, et al. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res 2000; 40:123.</a></li><li><a class="nounderline abstract_t">Bockbrader HN, Radulovic LL, Posvar EL, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol 2010; 50:941.</a></li><li><a class="nounderline abstract_t">Vollmer KO, von Hodenberg A, Kölle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung 1986; 36:830.</a></li><li><a class="nounderline abstract_t">Wong MO, Eldon MA, Keane WF, et al. Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol 1995; 35:622.</a></li><li><a class="nounderline abstract_t">Randinitis EJ, Posvar EL, Alvey CW, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003; 43:277.</a></li><li class="breakAll">Gabapentin package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf (Accessed on March 23, 2023).</li><li class="breakAll">Pregabalin package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021446s035,022488s013lbl.pdf (Accessed on March 23, 2023).</li><li><a class="nounderline abstract_t">Klein-Schwartz W, Shepherd JG, Gorman S, Dahl B. Characterization of gabapentin overdose using a poison center case series. J Toxicol Clin Toxicol 2003; 41:11.</a></li><li><a class="nounderline abstract_t">Schauer SG, Varney SM. Gabapentin overdose in a military beneficiary. Mil Med 2013; 178:e133.</a></li><li><a class="nounderline abstract_t">Fischer JH, Barr AN, Rogers SL, et al. Lack of serious toxicity following gabapentin overdose. Neurology 1994; 44:982.</a></li><li><a class="nounderline abstract_t">Bouchard J, Yates C, Calello DP, et al. Extracorporeal Treatment for Gabapentin and Pregabalin Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. Am J Kidney Dis 2022; 79:88.</a></li><li><a class="nounderline abstract_t">Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 2001; 42:790.</a></li><li><a class="nounderline abstract_t">Holtkamp M, Halle A, Meierkord H, Masuhr F. Gabapentin-induced severe myoclonus in a patient with impaired renal function. J Neurol 2006; 253:382.</a></li><li><a class="nounderline abstract_t">Desai A, Kherallah Y, Szabo C, Marawar R. Gabapentin or pregabalin induced myoclonus: A case series and literature review. J Clin Neurosci 2019; 61:225.</a></li><li><a class="nounderline abstract_t">Niruntarai S, Cherrington BD, Hodgman M. Seizure after massive gabapentin overdose [abstract]. Clin Toxicol 2018; 56:526.</a></li><li><a class="nounderline abstract_t">Isoardi KZ, Polkinghorne G, Harris K, Isbister GK. Pregabalin poisoning and rising recreational use: a retrospective observational series. Br J Clin Pharmacol 2020; 86:2435.</a></li><li><a class="nounderline abstract_t">Gorodetsky RM, Wiegand TJ, Kamali M. Seizures in the Setting of Large Pregabalin Overdose [abstract]. Clin Toxicol 2012; 50:322.</a></li><li><a class="nounderline abstract_t">Reedy SJD, Schwartz MD. A case series of recreational pregabalin overdose resulting in generalized seizures [abstract]. Clin Toxicol 2010; 18:616.</a></li><li><a class="nounderline abstract_t">Olaizola I, Ellger T, Young P, et al. Pregabalin-associated acute psychosis and epileptiform EEG-changes. Seizure 2006; 15:208.</a></li><li><a class="nounderline abstract_t">Haqqie SS, Grabe DW, Myint T, et al. Gabapentin induced acute kidney injury and management with hemodialysis [abstract]. Am J Kidney Dis 2015; 65:A41.</a></li><li><a class="nounderline abstract_t">Qiu X, Tackett E, Khitan Z. A case of gabapentin overdose induced rhabdomyolysis requiring renal replacement therapy. Clin Case Rep 2019; 7:1596.</a></li><li><a class="nounderline abstract_t">Bilgir O, Calan M, Bilgir F, et al. Gabapentin-induced rhabdomyolysis in a patient with diabetic neuropathy. Intern Med 2009; 48:1085.</a></li><li><a class="nounderline abstract_t">Choi MS, Jeon H, Kim HS, et al. A case of gabapentin-induced rhabdomyolysis requiring renal replacement therapy. Hemodial Int 2017; 21:E4.</a></li><li><a class="nounderline abstract_t">Tuccori M, Lombardo G, Lapi F, et al. Gabapentin-induced severe myopathy. Ann Pharmacother 2007; 41:1301.</a></li><li><a class="nounderline abstract_t">Krasowski MD. Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications. Pharmaceuticals (Basel) 2010; 3:1909.</a></li><li><a class="nounderline abstract_t">Kaufman KR, Parikh A, Chan L, et al. Myoclonus in renal failure: Two cases of gabapentin toxicity. Epilepsy Behav Case Rep 2014; 2:8.</a></li><li><a class="nounderline abstract_t">Lal R, Sukbuntherng J, Luo W, et al. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. Clin Ther 2012; 34:201.</a></li><li><a class="nounderline abstract_t">Jones H, Aguila E, Farber HW. Gabapentin toxicity requiring intubation in a patient receiving long-term hemodialysis. Ann Intern Med 2002; 137:74.</a></li><li><a class="nounderline abstract_t">Dogukan A, Aygen B, Berilgen MS, et al. Gabapentin-induced coma in a patient with renal failure. Hemodial Int 2006; 10:168.</a></li><li><a class="nounderline abstract_t">Hung TY, Seow VK, Chong CF, et al. Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia. Emerg Med J 2008; 25:178.</a></li><li><a class="nounderline abstract_t">Miller A, Price G. Gabapentin toxicity in renal failure: the importance of dose adjustment. Pain Med 2009; 10:190.</a></li><li><a class="nounderline abstract_t">Yoo L, Matalon D, Hoffman RS, Goldfarb DS. Treatment of pregabalin toxicity by hemodialysis in a patient with kidney failure. Am J Kidney Dis 2009; 54:1127.</a></li><li><a class="nounderline abstract_t">Lee DW, Lee HJ, Kim HJ, et al. Two cases of pregabalin neurotoxicity in chronic kidney disease patients. NDT Plus 2011; 4:138.</a></li><li><a class="nounderline abstract_t">Ocak M, Ucar C. The Effectiveness of Hemodialysis in case of Intoxication with Pregabalin. Journal of Emergency Medicine Case Reports 2019; 10:112.</a></li><li><a class="nounderline abstract_t">Ishikawa H, Takeshima M, Ishikawa H, et al. Pregabalin withdrawal in patients without psychiatric disorders taking a regular dose of pregabalin: A case series and literature review. Neuropsychopharmacol Rep 2021; 41:434.</a></li><li><a class="nounderline abstract_t">See S, Hendriks E, Hsiung L. Akathisia induced by gabapentin withdrawal. Ann Pharmacother 2011; 45:e31.</a></li><li><a class="nounderline abstract_t">Papanna B, Lazzari C, Kulkarni K, et al. Pregabalin abuse and dependence during insomnia and protocol for short-term withdrawal management with diazepam: examples from case reports. Sleep Sci 2021; 14:193.</a></li><li><a class="nounderline abstract_t">Çalışkan AM, İnanlı İ, Çalışkan S, Eren İ. Delirium After Pregabalin Withdrawal. Alpha Psychiatry 2021; 22:118.</a></li><li><a class="nounderline abstract_t">Du YT, Roberts AP, Torpy DJ. Seizure induced by sudden cessation of pregabalin in a patient with chronic kidney disease. BMJ Case Rep 2017; 2017.</a></li><li><a class="nounderline abstract_t">Barrueto F Jr, Green J, Howland MA, et al. Gabapentin withdrawal presenting as status epilepticus. J Toxicol Clin Toxicol 2002; 40:925.</a></li><li class="breakAll">Neurontin (gabapentin) [prescribing information]. New York, NY: Parke-Davis; October 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf (Accessed on April 24, 2023).</li><li><a class="nounderline abstract_t">Carrasco M, Rao SC, Bearer CF, Sundararajan S. Neonatal Gabapentin Withdrawal Syndrome. Pediatr Neurol 2015; 53:445.</a></li><li><a class="nounderline abstract_t">Loudin S, Murray S, Prunty L, et al. An Atypical Withdrawal Syndrome in Neonates Prenatally Exposed to Gabapentin and Opioids. J Pediatr 2017; 181:286.</a></li></ol></div><div id="topicVersionRevision">Topic 139762 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31786961" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Trends in gabapentin and baclofen exposures reported to U.S. poison centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27265421" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Gabapentin misuse, abuse and diversion: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28144823" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Abuse and Misuse of Pregabalin and Gabapentin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35290917" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Nonmedical use of gabapentin and opioid agonist medications in treatment-seeking individuals with opioid use disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30431483" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Gabapentin Abuse by Nasal Insufflation: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31766153" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Intranasal Pregabalin Administration: A Review of the Literature and the Worldwide Spontaneous Reporting System of Adverse Drug Reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28972983" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30140853" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pregabalin and the Risk for Opioid-Related Death: A Nested Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35552367" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Notes from the Field: Trends in Gabapentin Detection and Involvement in Drug Overdose Deaths - 23 States and the District of Columbia, 2019-2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12167463" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Gabapentin inhibits presynaptic Ca(2+) influx and synaptic transmission in rat hippocampus and neocortex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16376147" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The mechanisms of action of gabapentin and pregabalin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12665421" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pregabalin: a new anxiolytic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21320112" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26721643" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Gabapentin: Abuse, Dependence, and Withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30501608" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Acute phenibut withdrawal: A comprehensive literature review and illustrative case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23391959" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Phenibut dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10863139" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20147618" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical pharmacokinetics of pregabalin in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3730018" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pharmacokinetics and metabolism of gabapentin in rat, dog and man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7665723" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Disposition of gabapentin in anuric subjects on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12638396" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pharmacokinetics of pregabalin in subjects with various degrees of renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12638396" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pharmacokinetics of pregabalin in subjects with various degrees of renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12638396" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pharmacokinetics of pregabalin in subjects with various degrees of renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12645962" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Characterization of gabapentin overdose using a poison center case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23764159" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Gabapentin overdose in a military beneficiary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8190316" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Lack of serious toxicity following gabapentin overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34799138" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Extracorporeal Treatment for Gabapentin and Pregabalin Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422338" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16133721" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Gabapentin-induced severe myoclonus in a patient with impaired renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30381161" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Gabapentin or pregabalin induced myoclonus: A case series and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Seizure after massive gabapentin overdose [abstract]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32374500" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pregabalin poisoning and rising recreational use: a retrospective observational series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Seizures in the Setting of Large Pregabalin Overdose [abstract]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A case series of recreational pregabalin overdose resulting in generalized seizures [abstract]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16530431" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pregabalin-associated acute psychosis and epileptiform EEG-changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Gabapentin induced acute kidney injury and management with hemodialysis [abstract]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31428399" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A case of gabapentin overdose induced rhabdomyolysis requiring renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19525604" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Gabapentin-induced rhabdomyolysis in a patient with diabetic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27389284" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A case of gabapentin-induced rhabdomyolysis requiring renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17565043" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Gabapentin-induced severe myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20640233" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25667856" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Myoclonus in renal failure: Two cases of gabapentin toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22206794" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12093261" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Gabapentin toxicity requiring intubation in a patient receiving long-term hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16623669" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Gabapentin-induced coma in a patient with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18299377" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18721173" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Gabapentin toxicity in renal failure: the importance of dose adjustment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19493601" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment of pregabalin toxicity by hemodialysis in a patient with kidney failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25984138" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Two cases of pregabalin neurotoxicity in chronic kidney disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The Effectiveness of Hemodialysis in case of Intoxication with Pregabalin</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34382380" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pregabalin withdrawal in patients without psychiatric disorders taking a regular dose of pregabalin: A case series and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21652784" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Akathisia induced by gabapentin withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35082992" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pregabalin abuse and dependence during insomnia and protocol for short-term withdrawal management with diazepam: examples from case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36425938" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Delirium After Pregabalin Withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28473361" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Seizure induced by sudden cessation of pregabalin in a patient with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12507063" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Gabapentin withdrawal presenting as status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12507063" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Gabapentin withdrawal presenting as status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26278632" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Neonatal Gabapentin Withdrawal Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27889067" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : An Atypical Withdrawal Syndrome in Neonates Prenatally Exposed to Gabapentin and Opioids.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
